Piramal Pharma Solution business, a leading Contract Development and Manufacturing Organisation (CDMO), announces that the company’s site in Grangemouth, UK, has been selected as the winner of the most recent PPS Award for Excellence in Patient Centricity
The award, which is given out twice per year, goes to the Patient Awareness Council (PAC) at a PPS site in recognition of a specific program they initiated related to Patient Centricity. A core ideology of the company, Patient Centricity is built upon the principal that understanding the needs of patients and building an organisation that is dedicated to addressing those needs is foundational to the company. As part of the Patient Centricity onboarding initiative, employees at all fourteen of the company’s sites around the world received dedicated training on how to embrace the concept and make the program a reality. Patient Awareness Councils were formed at each site for the purpose of driving the idea forward at a local level.
According to Stuart Needleman, Chief Patient Centricity Officer at Piramal Pharma Solutions, “We received another strong set of nominations from Patient Awareness Councils for our latest Excellence in Patient Centricity Award. After much debate, senior management selected the Lunch and Learn project at Grangemouth as the winner from all the submissions. It received high marks for its concept, execution, and relevance to our goal of being a patient-centric CDMO.”
The Grangemouth PAC’s Lunch and Learn sessions were designed to raise knowledge of how the site’s expertise in developing and manufacturing antibody-drug conjugates (ADCs) relates to patients, the site staff, and the local community. In a presentation attended by close to half of the total staff in Grangemouth, the differences between ADCs and conventional therapies and why the modality has fewer side effects and improved outcomes in late-stage cancers were discussed. An abridged version of the presentation was given to members of a local Rotary club to raise awareness of the work done at Grangemouth and the benefits of ADCs.
PPS Grangemouth is recognized around the world as a leader in the development and manufacture of antibody-drug conjugates and other bioconjugates. The facility boasts two significant ADC capabilities: fit-for-purpose rapid development for early clinical materials and robust, scalable late phase development to support pivotal trials and commercial launch. By combining these skills with offerings from our other thirteen global facilities, including fill/finish, payloads, and peptides, we can provide integrated ADC services to customers looking for fast, simplified solutions.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “The timing of this award is significant, since we recently announced a major capacity expansion of the Grangemouth facility. We are investing in new manufacturing suites that will more than double our ADC production capacity and meet demand for commercial ADCs, strengthening our ability to service customers throughout the entire drug lifecycle.”